Isotonic designs for phase I cancer clinical trials with multiple risk groups
暂无分享,去创建一个
[1] John O'Quigley,et al. Continual Reassessment Method for Ordered Groups , 2003, Biometrics.
[2] S. Piantadosi,et al. Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.
[3] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[4] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[5] S. Piantadosi,et al. Dose-response models with covariates. , 1995, Biometrics.
[6] J O'Quigley,et al. Continual reassessment method: a likelihood approach. , 1996, Biometrics.
[7] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[8] J O'Quigley,et al. Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.
[9] William F Rosenberger,et al. Competing designs for phase I clinical trials: a review , 2002, Statistics in medicine.
[10] R Mackie,et al. A new approach to dose escalation in non-small-cell lung cancer. , 2001, International journal of radiation oncology, biology, physics.
[11] S Chevret,et al. The continual reassessment method in cancer phase I clinical trials: a simulation study. , 1993, Statistics in medicine.
[12] S. Chevret,et al. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. , 1991, Statistics in medicine.
[13] F. T. Wright,et al. Order restricted statistical inference , 1988 .
[14] A Rogatko,et al. Patient specific dosing in a cancer phase I clinical trial , 2001, Statistics in medicine.
[15] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[16] R. Schilsky,et al. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. , 1996, Pharmacogenetics.
[17] J G Ibrahim,et al. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method , 2001, Statistics in medicine.
[18] André Rogatko,et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D H Leung,et al. Isotonic designs for phase I trials. , 2001, Controlled clinical trials.